SEP 24, 2014 12:00 PM PDT

The Accurate Prediction of Ligand Binding Free Energies

OOPS! THAT EXPERIMENT FAILED...

It's not your fault! Something went wrong with our formula.
Please begin your experiment again by clicking here.

If this error continues to occur please contact us at support@labroots.com.

Speakers
  • Principal at Disruptive Biomedical, LLC, Professor of Practice at MIT & Northwestern
    Biography
      Mark Murcko is Principal at Disruptive Biomedical, serving as an independent consultant as well as a Professor of Practice at MIT. Until 2011 Mark was CTO and Chair of the Scientific Advisory Board at Vertex Pharmaceuticals, and responsible for incorporation of disruptive technologies across global R&D.  He is co-inventor of Incivek (telaprevir) as well as Agenerase (amprenavir) and Lexiva (fosamprenavir) for HIV. In addition, he guided the early efforts of Vertex's cystic fibrosis program that produced Kalydeco (ivacaftor) and multiple other CF compounds currently in late-stage development.  Mark is also a co-inventor of 8 other clinical candidates for cancer, inflammation and infectious disease.  Prior to Vertex, Mark worked at Merck Sharpe & Dohme where he worked on the carbonic anhydrase program that produced the glaucoma drug Trusopt (dorzolamide). He was the co-organizer of the 2008 ACS National Medicinal Chemistry Symposium and served as Chair of the 2013 Gordon Research Conference in Medicinal Chemistry.

    Abstract:
    In the past decade, we have witnessed an explosion in the availability of high-resolution structural information that sheds light on the binding of diverse classes of ligands to both soluble proteins and integral membrane receptors. From orthosterics to allosterics, from tiny fragments to enormous rule-breakers, we know more than ever about how ligands bind. However, the ability to accurately predict binding free energies has lagged behind, significantly limiting the utility of this structural information. The good news is that in the past few years there has been a breakthrough in ligand binding free energy prediction. I will summarize the evidence and suggest ways to effectively deploy this new capability

    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    AUG 13, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 13, 2019 09:00 AM PDT
    DATE: August 13, 2019TIME: 9:00am PT, 12:00pm ET, 5:00pm BST Molecular complexes are major constituents of cells, hence unraveling their mechanisms is key to fuller comprehension of c...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources